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Objective: Pulsatile and nonpulsatile left ventricular assist devices are effective in managing congestive heart
failure. Despite early evidence for clinical efficacy, the long-term impact of nonpulsatile flow on end-organ
function remains to be determined. Our goal was to compare rates of gastrointestinal bleeding in nonpulsatile
and pulsatile device recipients.
Methods: In a retrospective review of 101 left ventricular assist device recipients (55 nonpulsatile, 46 pulsatile)
fromOctober 31, 2003, to June 1, 2007, at a single center, gastrointestinal bleeding was defined as guaiac-positive
stool with hemoglobin drop requiring transfusion of at least 2 units of packed red blood cells. To assess bleeding
risk outside the initial postoperative course, any patients with a device in place for 15 days or less was excluded.
Results: Twelve nonpulsatile and 3 pulsatile left ventricular assist device recipients had gastrointestinal bleeding
16 days or longer after device implantation. The event rates were 63 events/100 patient-years for nonpulsatile
devices and 6.8 events/100 patient-years for pulsatile devices (P ¼ .0004). This difference persisted for bleeding
occurring 31 days or longer after device implantation, with 46.5 events/100 patient-years for nonpulsatile devices
versus 4.7 events/100 patient-years for pulsatile devices (P ¼ .0028). Mortalities were similar between groups
(15% nonpulsatile vs 17% pulsatile, P ¼ .6965).
Conclusion: Patients with nonpulsatile left ventricular assist devices appear to have a higher rate of gastro-
intestinal bleeding events than do pulsatile left ventricular assist device recipients. Further prospective eval-
uation is needed to determine potential etiologies and strategies for reducing gastrointestinal bleeding in this
population.Five million Americans carry the diagnosis of congestive
heart failure (CHF).1 The large discrepancy between donor
organ supply and demand has necessitated the development
of alternative methods for treating cardiac failure. In addi-
tion, a growing number of people need cardiac support
but are ineligible for heart transplantation. The clinical suc-
cess of ventricular assist devices offers an innovative strat-
egy for increasing the life expectancy of patients with CHF.
In the Randomized Evaluation of Mechanical Assistance
for the Treatment of Congestive Heart Failure (RE-
MATCH) trial,2 left ventricular assist device (LVAD)
recipients had 1- and 2-year survivals 2 times greater
than those of patients treated with traditional medical ther-
apy alone. This landmark trial established the LVAD as
a successful alternative to medical therapy for patients not
eligible for heart transplantation.2 Additional studies have
demonstrated similar efficacy for LVAD use as a bridge
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Now that clinical efficacy has been confirmed, we must
direct our focus toward identification of the best device
mechanism for delivering mechanical support. The LVADs
being used in clinical practice can be divided into two cate-
gories according to the type of flow they provide: pulsatile
and nonpulsatile. The earliest Food and Drug Administra-
tion (FDA)–approved devices provide pulsatile flow
mimicking the native cardiac physiology. Unfortunately,
features of the pulsatile design often limit device durability,
necessitating replacement within 15 to 18 months. In addi-
tion, size and weight limit this device type’s use in children
and small adults. The newer, more compact nonpulsatile de-
vices provide improved ease of implantation and have the
potential for improved durability. Preliminary data suggest
that pulsatile and nonpulsatile devices have comparable out-
comes and equivalent risk profiles.4 Early follow-up of non-
pulsatile device recipients demonstrate improved functional
status and quality of life at 3 months, with a 6-month sur-
vival of 75%.5 As survival improves, long-term follow-up
of these patients becomes essential to demonstrate efficacy
and safety beyond the first postoperative year.
The impact of nonpulsatile flow on end-organ function
over time remains unknown. A 6-month follow-up of 10 pa-
tients implanted with the Jarvik 2000 device (Jarvik Heart,
Inc, New York, NY) demonstrated not only preservationgery c January 2009
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AS ¼ aortic stenosis
AVM ¼ arteriovenous malformation
BMI ¼ body mass index
BTT ¼ bridge to transplant
CHF ¼ congestive heart failure
DT ¼ destination therapy
FDA ¼ Food and Drug Administration
HMW ¼ high–molecular weight
INR ¼ international normalized ratio
LVAD ¼ left ventricular assist device
REMATCH ¼ Randomized Evaluation of
Mechanical Assistance for the
Treatment of Congestive Heart
Failure
vWF ¼ von Willebrand factor
of but also improvement in hepatic and renal function.6
Some end organs, however, may be more sensitive to non-
pulsatile flow. Early case reports have suggested that gastro-
intestinal bleeding may be a more frequent complication
with nonpulsatile devices. Letsou and colleagues7 reported
that of 21 patients who received a nonpulsatile LVAD, 3
had a gastrointestinal bleeding event.7 We sought to investi-
gate this potential complication by comparing the incidence
of gastrointestinal bleeding between patients implanted with
nonpulsatile and pulsatile LVADs at a single center during
the same time period.
MATERIALS AND METHODS
Patients
After obtaining approval from the institutional review board, we retro-
spectively reviewed the cases of all patients with LVADs implanted from
October 31, 2003, to June 1, 2007, at the University of Minnesota. The start
of the study inclusion period coincides with the placement of the first
nonpulsatile device at our center. There were 109 patients who underwent
ventricular assist device placement (56 nonpulsatile and 53 pulsatile) during
this period. We excluded 2 patients who received right ventricular assist de-
vices. In an attempt to assess bleeding risk outside the initial postoperative
course, we excluded any patient with a device in place for 15 days or less (1
nonpulsatile and 5 pulsatile), leaving 101 patients for data analysis. None of
the 6 patients with an implant duration of 15 days or less had any gastroin-
testinal bleeding events. Ten patients underwent multiple LVAD place-
ments. For these patients, only the time after the first LVAD implant was
included for data analysis.
Device Placement
LVAD candidates include all patients who are in New York Heart Asso-
ciation functional class IV CHF and have potential for reversible secondary
end-organ failure. The eligible patients in this studywere classified as receiv-
ing the LVAD as BTT or destination therapy (DT). BTT signifies eligibility
for cardiac transplantation with rapid deterioration or ongoing heart failure
necessitating mechanical support to sustain life. Patients who do not qualify
for transplant may have the option of LVAD placement as DT to extend lon-
gevity. LVADs implanted for both BTT and DT may be either pulsatile orThe Journal of Thoracic and Cnonpulsatile devices, depending on a number of factors. All patients who re-
ceive nonpulsatile devices are enrolled in one of the ongoing FDA investiga-
tional device exemption protocols. The inclusion criteria for theBTT andDT
investigational device exemption trials are listed in the Appendix. Patients
not meeting inclusion criteria receive an FDA-approved pulsatile device
(HeartMate XVE; Thoratec Corporation, Pleasanton, Calif). Any patient, re-
gardless of therapy classification asBTTorDT,with rapid cardiac failure ne-
cessitating temporary placement of a Levitronix (Levitronix LLC,Waltham,
Mass) LVAD received a pulsatile device once their clinical condition had
stabilized. There were 13 patients in our cohort in whom pulsatile LVAD
placement was preceded by a Levitronix LVAD.
Anticoagulation
Nonpulsatile device recipients are placed on a regimen of warfarin
sodium and aspirin, with a goal of an international normalized ratio (INR)
of 1.5 to 3. The protocol for pulsatile device recipients is daily aspirin.
Peptic Ulcer Prophylaxis
The clinical practice at our institution is to use an intravenous proton-
pump inhibitor while the patient is hospitalized, with transition to oral pro-
ton-pump inhibitor therapy in preparation for discharge. The proton-pump
inhibitor is continued indefinitely in the outpatient setting.
Data Collection
Data were collected from the University of Minnesota ventricular assist
device database and patient medical records. Preoperative variables
included the following: age, sex, diabetes status, body mass index (BMI),
sodium concentration, albumin concentration, and etiology of heart failure.
Bypass time and device brand were recorded for each patient. Bypass time
included the time required to implant the ventricular assist device and to
complete any necessary cardiac repairs. The outpatient follow-up data
were collected by recording vital signs and laboratory values documented
from two subsequent cardiology visits at least 1 month apart. These two
values were averaged for each patient. Specific follow-up data collected
were as follows: heart rate, systolic and diastolic blood pressures, medica-
tion profile, sodium, creatinine, albumin, liver function tests, INR, and
activated partial thromboplastin time. When a gastrointestinal bleeding
event occurred, the data were averaged from the two clinic visits preceding
the gastrointestinal bleeding date.
The development of a gastrointestinal bleeding event was the primary
end point for this study. Gastrointestinal bleeding was defined as
a guaiac-positive stool and a hemoglobin drop requiring transfusion of at
least 2 units of packed red blood cells. INR and activated partial thrombo-
plastin time were documented at presentation, before transfusion. Gastroin-
testinal bleeding events were classified according to time from device
implantation as early (16–30 days after implant) or late (31 days or later).
For the 3 patients who had multiple gastrointestinal bleeding events, only
the first event was included for data analysis.
Statistical Analysis
Data for all continuous variables (age, mean arterial pressure, pulse
width, laboratory values, implant duration, and bypass time) are presented
as mean SE. The Student t test was used to test for statistically significant
differences between groups. Binary variables (sex, diabetes status, and
device purpose) are presented as totals with percentages and were compared
with a c2 statistic. The primary outcome, gastrointestinal bleeding, was cal-
culated as a bleeding rate of events per 100 patient-years with LVAD and
modeled with Poisson regression by the Genmod procedure (SAS version
9.1; SAS Institute, Inc, Cary, NC). Kaplan–Meier survival curves were
used to demonstrate bleeding rates with time. BMI was converted to a cate-
goric variable, either greater than 29 kg/m2 or less than or equal to 29 kg/m2.
We had full access to the data and take responsibility for its integrity. All of
us have read and agree to the article as written.ardiovascular Surgery c Volume 137, Number 1 209
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PTABLE 1. Baseline characteristics
Nonpulsatile (N ¼ 55) Pulsatile (N ¼ 46) P value
Age (y, mean  SD) 55.1  1.9 55.7  1.8 .8433
Sex (male) 42 (76%) 39 (85%) .2903
Diabetes (No.) 18 (35%, n ¼ 51) 24 (53%, n ¼ 45) .0754
Preoperative body mass index (kg/m2, mean  SD) 27.1  0.8 30.9  1.0 (n ¼ 45) .0040
Preoperative sodium (mEq/L, mean  SD) 136.0  0.9 (n ¼ 50) 137.0  0.7 (n ¼ 40) .3858
Preoperative albumin (g/dL, mean  SD) 3.6  0.1 (n ¼ 50) 3.3  0.1 (n ¼ 34) .0445
Duration of support (d, mean  SD) 200.4  21.5 302.7  27.5 .0043
Device purpose (No.)
Bridge to transplant 46 (84%) 38 (83%) .8907
Destination therapy 9 (16%) 8 (17%) .8907
Cardiopulmonary bypass time (min, mean  SD) 124.1  5.3 149.0  8.1 .0115
Device type (No.) <.0001
HeartMate II* 38 (69%)
MicroMedy 8 (15%)
VentrAssistz 9 (16%)
HeartMate XVE* 46 (100%)
Deaths (No.) 8 (15%) 8 (17%) .6965
*Thoratec Corporation, Pleasanton, Calif. yMicroMed Cardiovascular, Inc, Houston, Tex. zVentracor Inc, Foster City Calif.RESULTS
Patients
A total of 101 patients were available for study inclusion
and data analysis after exclusion of patients with right ven-
tricular assist devices or a device implant duration of 15 days
or less. Of these 101 patients, 55 received nonpulsatile
LVADs and 46 received pulsatile LVADs. The baseline
characteristics for the nonpulsatile and pulsatile device
recipients are outlined in Table 1. Preoperative screening
revealed no difference in the gastrointestinal bleeding his-
tory between nonpulsatile and pulsatile LVAD recipients.
Device purpose, diabetes status, age, sex, and preoperative
sodium level did not differ significantly between groups.
There was no difference in mortality (15% for nonpulsatile
vs 17% for pulsatile, P ¼ .6965). The pulsatile group had
a slightly lower preoperative albumin level (3.3  0.1 vs
3.6  0.1 g/dL), a difference that did reach significance
(P ¼ .0445). The nonpulsatile group had a significantly
lower preoperative BMI (27.1  0.8 vs 30.9  1.0 kg/m2,
P ¼ .0040) and a shorter bypass duration (124.1  5.3 vs
149.0  8.1 minutes P ¼ .0115). The pulsatile group had
a significantly longer implant duration (200.4  21.5 vs
302.7  27.5 days, P ¼ .0043).
Primary Outcome
The primary outcome of interest was the rate of gastroin-
testinal bleeding in nonpulsatile versus pulsatile device
recipients. A gastrointestinal bleeding event rate was calcu-
lated with the duration of LVAD support as the time at risk
(denominator). This rate comparison was calculated three
ways, as shown in Table 2. All bleeding events represents
every gastrointestinal bleeding event that occurred 16 days
or later after implant and includes multiple bleeding events210 The Journal of Thoracic and Cardiovascular Suin the same patient. Two patients in this group had 3 gastro-
intestinal bleeding events each, and 1 patient had 4 bleeding
events. The rate for all gastrointestinal bleeding events was
nearly 10 times higher in the nonpulsatile group. Time at risk
for early and late gastrointestinal bleeding rates begins with
device implantation and ends with the first gastrointestinal
bleeding event occurring 15 (early) or 31 (late) days after im-
plantation. The nonpulsatile early and late gastrointestinal
bleeding rates were 7 and 10 times higher, respectively,
than were pulsatile bleeding rates (Table 2). There were 15
first-time gastrointestinal bleeding events after 15 days, 12
in the nonpulsatile group and 3 in the pulsatile group,
(P ¼ .0313, c2 test).
The time to first gastrointestinal bleeding event after 15
days is represented in the Kaplan–Meier curve shown in Fig-
ure 1. The log-rank c2 test statistic for homogeneity across
the device type strata is 7.4565, with a P value of .0063.
Postimplant Comparisons
The postimplant characteristics of patients receiving
the two device types are summarized in Table 3. Creatinine,
TABLE 2. Gastrointestinal bleeding event rates
Implant duration
Nonpulsatile
(n ¼ 55)
Pulsatile
(n ¼ 46) P value
First bleeding event after 15 d
Events/100 patient-y 47.7 7.3 .0036
Total 12 3 .0013
First bleeding event after 30 d
Events/100 patient-y 46.5 4.7 .0028
Total 12 2 .0114
All bleeding events after 15 d
(events/100 patient-y)
63 6.8 .0004rgery c January 2009
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Psodium, albumin, liver function tests (aspartate aminotrans-
ferase, alanine aminotransferase, total bilirubin), and
activated partial thromboplastin time were similar between
groups. As expected in the post implantation comparisons,
heart rate (nonpulsatile 84.2  1.6 beats/min vs pulsatile 68.2
 1.6 beats/min) and pulse width (nonpulsatile 32.2  1.5 vs
pulsatile 59.0  2.6) were significantly different (P< .0001
for both), but mean arterial pressure was not (nonpulsatile
81.1  1.8 mm Hg vs pulsatile 84.8  1.9 mm Hg,
P ¼ .1727). Anticoagulation with warfarin sodium in the
nonpulsatile group resulted in a significant difference in INR
(nonpulsatile 2.0  0.1 vs pulsatile 1.6  0.1, P¼ .0100).
Nonpulsatile Group: Comparisons Between Those
With and Without Gastrointestinal Bleeding
Finally, within the nonpulsatile device group, we com-
pared characteristics of patients who had gastrointestinal
bleeding after 15 days with those of the patients who did
not have bleeding (Table 4). The only trends were toward
lower BMI and longer duration of LVAD support in patients
with gastrointestinal bleeding events. There were no
significant differences in device purpose, diabetes status,
age, sex, preoperative albumin, or bypass time between
nonpulsatile device recipients with and without bleeding.
Follow-up averages of heart rate, mean arterial pressure,
pulse width, liver function tests, and creatinine were similar
as well. The mortality was different between patients with
and without bleeding with 3 (25%) and 5 (12%) deaths,
respectively, although this difference was not statistically
significant (P ¼ .2453). There was a trend toward longer
implant duration in patients with gastrointestinal bleeding
(no bleeding 173.9  19.5 days vs bleeding 295.7  64.5
days, P ¼ .0939). There was no significant difference in
INR for those with and without bleeding (2.0  0.1 vs 2.1
 0.2, P ¼ .8134).
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FIGURE 1. Gastrointestinal (GI) bleeding events with time after left ven-
tricular assist device placement in 101 patients.The Journal of Thoracic andDISCUSSION
LVADs are effectively prolonging life for patients
with CHF. As life expectancy increases, optimizing quality
of life becomes imperative. Previous trials have demonstrated
equivalent survival with pulsatile and nonpulsatile ventricular
assist devices.4,5 Preliminary studies evaluating the efficacy
and risk profile of nonpulsatile flow devices have not specifi-
cally addressed the incidence of gastrointestinal bleeding.
Letsou and colleagues7 reported 3 cases of gastrointestinal
bleeding among the first 21 Jarvik 2000 nonpulsatile LVAD
recipients. Hetzer and associates8 had 1 case of persistent gas-
trointestinal bleeding among the first 24 recipients of the Incor
nonpulsatile pump (Berlin Heart GmbH, Berlin, Germany).8
Gastrointestinal bleeding was not recognized as a significant
cause of postoperative morbidity in the REMATCH trial or
the pulsatile FDA study protocols (Novacor; World Heart
Inc, Oakland, Calif; and HeartMate XVE).2,9,10
In our series of 101 patients, the rate of gastrointestinal
bleeding was significantly higher for patients who received
nonpulsatile LVADs. There were 63 gastrointestinal bleed-
ing events per 100 patient-years in nonpulsatile device
recipients, versus 6.8 in the pulsatile group (P ¼ .0004).
Postoperative creatinine and liver function tests were within
reference ranges for both groups, indicating good end-organ
function. Markers for end-organ dysfunction were similarly
absent in the nonpulsatile device recipients who had gastro-
intestinal bleeding events. The pulsatile group was more
likely to begin the device period in poorer health, with 13
patients requiring emergency Levitronix LVAD placement
before placement of the pulsatile device. Nonpulsatile de-
vices are only available to patients enrolled in one of the
ongoing FDA investigational device exemption protocols.
TABLE 3. Postimplant characteristics
Nonpulsatile
(N ¼ 55) Pulsatile
(N ¼ 46)Mean ± SE n P value
Heart rate (beats/min) 84.2  1.6 49 68.2  1.6 42 <.0001
Mean arterial pressure
(mm Hg)
81.1  1.8 49 84.8  1.9 42 .1727
Pulse width (mm Hg) 32.2  1.5 49 59.0  2.6 42 <.0001
Creatinine (mg/dL) 1.3  0.1 51 1.3  0.1 44 .5588
Sodium (mEq/L) 140.1  0.3 51 140.7  0.4 43 .3055
Albumin (g/dL) 3.9  0.1 50 3.9  0.1 39 .8043
Alanine aminotransferase
(U/L)
38.2  6.5 51 33.1  2.9 38 .5221
Aspartate
aminotransferase (U/L)
50.7  4.8 51 40.4  3.1 37 .1034
Total bilirubin (mg/dL) 1.5  0.7 49 0.8  0.1 38 .3239
International normalized
ratio
2.0  0.1 51 1.6  0.1 23 .0100
Activated partial
thromboplastin
time (seconds)
42.0  1.6 46 40.9  8.0 9 .8946
All values represent an average from two subsequent follow-up visits 1 month apart.Cardiovascular Surgery c Volume 137, Number 1 211
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PTABLE 4. Comparison of nonpulsatile device recipients with and without gastrointestinal bleeding events
No bleeding (N ¼ 43) Bleeding (N ¼ 12) P value
Age (y, mean  SD) 53.8  2.1 60.1  4.5 .2236
Sex (male) 32 (74%) 10 (83%) .5204
Diabetes (No.) 14 (34%, n ¼ 41) 4 (40%, n ¼ 10) .7284
Preoperative body mass index (kg/m2, mean  SD) 28.0  0.9 23.9  1.8 .0513
Preoperative sodium (mEq/L, mean  SD) 136.3  1.0 (n ¼ 40) 135.1  1.8 (n ¼ 10) .6072
Preoperative albumin (g/dL, mean  SD) 3.7  0.1 (n ¼ 40) 3.4  0.2 (n ¼ 10) .2509
Etiology of heart failure (No.) (n ¼ 42) (n ¼ 12) .2531
Acute cardiomyopathy 1 (2%) 2 (17%)
Chronic cardiomyopathy 15 (36%) 2 (17%)
Acute ischemia 2 (5%) 1 (8%)
Chronic ischemia 22 (52%) 7 (58%)
Other 2 (5%) 0
Duration of support (mo, mean  SD) 173.9  19.5 295.7  64.5 .0939
Device purpose (No.)
Bridge to transplant 37 (86%) 9 (75%) .3604
Destination therapy 6 (14%) 3 (25%) .3604
Cardiopulmonary bypass time (min, mean  SD) 123.1  6.1 (n ¼ 43) 127.6  10.6 (n ¼ 11) .7364
Device type (No.)
HeartMate II* 29 (67%) 9 (75%) .1539
MicroMedy 5 (12%) 3 (25%)
VentrAssistz 9 (21%) 0
International normalized ratio (mean  SD) 2.0  0.1 (n ¼ 41) 2.1  0.2 (n ¼ 10) .8134
Aspartate aminotransferase (U/L, mean  SD) 53.0  5.9 (n ¼ 41) 41.5  3.6 (n ¼ 10) .3525
Alanine aminotransferase (U/L, mean  SD) 41.2  8.0 (n ¼ 41) 25.6  3.5 (n ¼ 10) .3452
Total bilirubin (mg/dL, mean  SD) 1.7  0.9 (n ¼ 39) 0.8  0.1 (n ¼ 10) .6089
Creatinine (mg/dL, mean  SD) 1.2  0.1 (n ¼ 41) 1.4  0.2 (n ¼ 10) .4728
Mean arterial pressure (mm Hg, mean  SD) 82.5  2.0 (n ¼ 39) 75.9  4.5 (n ¼ 10) .2067
Pulse width (mean  SD) (mm Hg) 31.5  1.9 (n ¼ 39) 34.8  2.1 (n ¼ 10) .4067
Heart rate (beats/min, mean  SD) 85.2  2.0 (n ¼ 39) 80.4  2.2 (n ¼ 10) .2375
Deaths (No.) 5 (12%) 3 (25%) .2453
All postoperative values represent an average from two subsequent follow-up visits 1 month apart. *Thoratec Corporation, Pleasanton, Calif. yMicroMed Cardiovascular, Inc,
Houston, Tex. zVentracor Inc, Foster City Calif.Therefore nonpulsatile device recipients had enough clinical
stability to await completion of the 1- to 2-day informed con-
sent and randomization process before device placement.
The pulsatile group had longer bypass times (149.0  8.1
vs 124.1  5.3 minutes, P ¼ .0115), further increasing the
risk for bowel ischemia and thus potentially the risk for gas-
trointestinal bleeding. Despite these risk factors, the pulsatile
group demonstrated the lower incidence of gastrointestinal
bleeding.
Among the 3 pulsatile device recipients with bleeding
events, 2 events were due to ischemic bowel near the time
of death. The third pulsatile device recipient with bleeding
had sepsis during his gastrointestinal bleeding, with an inde-
terminate source despite an extensive work-up. Twelve
patients in the nonpulsatile device group had bleeding
events: 4 had documented arteriovenous malformations
(AVMs) and 5 bled from anatomic problems, including
polyps, gastric feeding tube, and mucosal erosion presumed
related to gastroesophageal reflux. We were unable to iden-
tify a discrete source for bleeding in the remaining 3 patients.212 The Journal of Thoracic and Cardiovascular SuThe working diagnosis for 2 of these patients was small
bowel AVM. The final patient was believed to have ische-
mic bowel.
One obvious criticism of this study is the difference in
anticoagulation between the two groups. Nonpulsatile de-
vice recipients receive anticoagulation with warfarin sodium
to an INR goal of 1.5 to 3. Pulsatile device recipients do not
receive anticoagulation. Both nonpulsatile and pulsatile
device recipients take a daily aspirin tablet. Unlike earlier
case reports, in which bleeding continued until the time of
transplant, all of the gastrointestinal bleeding in this series
responded to an interruption in anticoagulation and lowering
of the pump speed to allow greater pulsatile flow. There was
no significant difference between the average INR observed
at the time of bleeding in nonpulsatile device recipients and
the average INR at follow-up in those without bleeding.
Comparing LVAD gastrointestinal bleeding rates to bleed-
ing complications in patients receiving anticoagulation for
other reasons suggests that our findings are not due to anti-
coagulation alone. The gastrointestinal bleeding rate in thergery c January 2009
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Pnonpulsatile group was much greater than the rate of all
types of bleeding in patients receiving anticoagulation after
placement of a mechanical valve. Cannegieter and co-
workers9 reported a bleeding complication rate of 2.68 to
4.6 events/100 patient-years in mechanical valve recipients
with combined antiplatelet and warfarin therapy. Levine
and colleagues10 studied patients receiving anticoagulation
for any reason and found hemorrhagic complication rates
of 5.7% per year. Our finding of 63 gastrointestinal bleeding
events/100 patient-years in nonpulsatile device recipients
clearly exceeds that seen in patients receiving anticoagula-
tion for other reasons. In addition, the INR range targeted
for our patient population is much lower than the levels
reported in these other studies.
If anticoagulation alonewere the cause for our findings,we
would expect to see a higher rate of bleeding from all causes
in nonpulsatile device recipients. Overall bleeding rates for
patients with nonpulsatile and pulsatile LVADs, however,
are quite similar. The REMATCH trial had a bleeding rate
at 6-month follow-up of 42% for the 68 pulsatile LVAD re-
cipients.2 The Texas Heart Institute follow-up of 280 Heart-
Mate pulsatile LVAD recipients reported an all-cause
bleeding rate of 48%.3 Bleeding from any cause requiring
2 units of blood in the HeartMate II LVAD (nonpulsatile)
trial occurred in 53% of the 133 patients followed up for
180 days after device implantation.5 Our findings demon-
strate an isolated increase in gastrointestinal bleeding for pa-
tients with nonpulsatile devices, despite similar overall
bleeding rates in nonpulsatile and pulsatile LVAD recipients.
Patients with aortic stenosis (AS) demonstrate a similar
isolated increase in gastrointestinal bleeding. In 1958,
Heyde11 described an association between AS and gastroin-
testinal bleeding. Follow-up studies have found a 100-fold
increase in the risk for gastrointestinal bleeding in patients
with AS.12 Patients with gastrointestinal angiodysplasia
who acquire AS demonstrate a decrease in high–molecular
weight (HMW) multimers of von Willebrand factor
(vWF). Warkentin and coworkers13 first described this ac-
quired von Willebrand disease in 1992 as the potential link
between gastrointestinal bleeding and AS. Later, Veyradier
and associates14 demonstrated that patients with valvular
heart disease had low levels of the largest multimers of
vWF. HMW vWF multimers are believed essential for
platelet-mediated hemostasis and prevention of bleeding in
high-shear areas. The tortuous vessels seen in gastrointesti-
nal angiodysplasia demonstrate high-shear stress blood
flow. In AS, deformation of vWF as it crosses the calcific
aortic valve results in a structural change, leading to proteol-
ysis and a decrease in the number of circulating HMWmulti-
mers.12,15 After aortic valve replacement, HMW vWF
multimer levels rise and gastrointestinal bleeding stops.15,19
Hypothetically, the continuous impeller mechanism of the
nonpulsatile LVAD pump may result in vWF deformation,
proteolysis, and ultimately deficiency of HMW vWFThe Journal of Thoracic andmultimers. Patients with preexisting gastrointestinal angio-
dysplasia would be at risk for gastrointestinal bleeding under
these conditions. Prospective evaluation of HMW vWF
levels before and after nonpulsatile and pulsatile device
placement is underway to test this hypothesis. Potapov and
colleagues16 have demonstrated that in some settings
a nonpulsatile LVAD can generate pulsatile flow as a result
of improved contractility of the recovering left ventricle. De-
creasing nonpulsatile device flow could result in pulsatile
blood flow and potentially decrease vWF deformation and
proteolysis. Restoration of HMW levels in this way could
prevent or resolve gastrointestinal bleeding.
Nonpulsatile flow may actually increase the development
of gastrointestinal angiodysplasia. Investigators have pro-
posed that the narrow pulse pressure that occurs in AS and
in nonpulsatile device recipients may increase intraluminal
pressure and dilate mucosal veins, leading to AVM patho-
genesis.7 These AVMs are believed to be more vulnerable
to bleeding during stress and anticoagulation.7,14 Cappell
and Lebwohl17 have suggested that narrow pulse pressure
triggers an increase in sympathetic tone, causing smooth
muscle relaxation, arteriovenular dilatation, and ultimately
arteriovenous malformation. Saito and colleagues18 exam-
ined sheep implanted with nonpulsatile LVADs and demon-
strated thinning of the medial layer of the ascending aorta.
Whether there are such changes throughout the arterial vas-
cular system in human beings is unknown.
CONCLUSIONS
We have documented an increased rate of gastrointestinal
bleeding in patients implanted with nonpulsatile LVADs rel-
ative to that seen with pulsatile flow devices. The bleeding
rate was higher than would be expected from anticoagula-
tion alone. Propensity toward arteriovenous malformation
in combination with low levels of hemostasis-enhancing
HMW von Willebrand factor multimers provides casual
mechanism. Further prospective investigation is required
to confirm these findings and to identify risk factors for gas-
trointestinal bleeding in this population.
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2006;81:490-4.Appendix. Nonpulsatile investigational device exemption protocol example inclusion and exclusion criteria
Inclusion Criteria
1. Patient or legal representative has signed an informed
consent form.
2. Patient is listed for transplant.
3. Body surface area is at least 1.2 m2.
4. New York Heart Association functional class IV heart
failure symptoms are present.
5. Female patients with childbearing potential must agree to
use adequate contraceptive precautions (defined as oral
contraceptives, intrauterine devices, surgical contracep-
tion, or a combination of condom and spermicide) for
the duration of the study.
6. Patient is receiving inotropic support, if tolerated.
7. Despite medical therapy, the patient must meet one of the
following criteria:
a. no contraindication for listing as status 1A or
b. no contraindication for listing as status 1B and meet-
ing the following hemodynamic criteria (collected
within 48 hours of enrollment):
i. pulmonary capillary wedge pressure or pulmonary
artery diastolic pressure (PAD) of at least 20 mm
Hg and
ii. cardiac index no greater than 2.2 L/(min $ m2) or
systolic blood pressure no greater than 90 mm Hg.
Exclusion Criteria
1. Etiology of heart failure is due to or associated with uncor-
rected thyroid disease, obstructive cardiomyopathy, peri-
cardial disease, amyloidosis, or restrictive cardiomyopathy.
2. Technical obstacles pose an inordinately high surgical
risk in the judgment of the investigator.
3. Any ongoing mechanical circulatory support other than
intra-aortic balloon counterpulsation is present.
4. BMI is 40 kg/m2 or greater.
5. Pregnancy test result is positive in woman of childbear-
ing potential.
6. Mechanical aortic cardiac valve is present and will not be
converted to a bioprosthesis at the timeofLVAD implant.
7. Patient has a history of cardiac transplant.
8. Platelet count is no higher than 50,000 cells/mL.
9. There is evidence of an untreated aortic aneurysm at
least 5 cm in size.
10. Psychiatric disease, irreversible cognitive dysfunction,
or psychosocial issues are likely to impair compliance
with the study protocol and LVAD management.
11. An active, uncontrolled infection is present.
12. Patient has intolerance to anticoagulant or antiplatelet
therapies or any other perioperative or postoperative
therapy the investigator may mandate according to the
patient’s health status.
13. Any one of the following risk factors for and indicators
of severe end-organ dysfunction or failure is present:
a. INR of at least 2.5 not caused by anticoagulant therapy
of clopidogrel bisulfate (INN clopidogrel) administra-
tion within 5 days;
b. total bilirubin greater than 5 mg/dL, or shock liver (eg,
transaminases greater than 2000 U/liter), or biopsy-
proven liver cirrhosis;
c. history of severe chronic obstructive pulmonary dis-
ease or severe restrictive lung disease;
d. fixed pulmonary hypertension, with a most recent
peripheral vascular resistance greater than 6 Wood
units, that is unresponsive to pharmacologic interven-
tion;gery c January 2009
Crow et al Cardiopulmonary Support and Physiologye. history of unresolved stroke or uncorrectable cerebro-
vascular disease;
f. serumcreatinineof at least 3.5mg/dLor theneed for long-
term renal replacement therapy (eg, long-term dialysis);
g. significant peripheral vascular disease accompanied
by rest pain or extremity ulceration.The Journal of Thoracic and C14. The patient has moderate to severe aortic insufficiency
without plans for correction during pump implantation
surgery.
15. The patient is participating in any other clinical investi-
gation that is likely to confound study results or affect
study outcome.ardiovascular Surgery c Volume 137, Number 1 215
C
S
P
